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Abstract 
Purpose.  
To describe real-world use of lanreotide combination therapy for acromegaly. 
Patients and methods.  
ACROCOMB is a retrospective observational Spanish study of patients with active acromegaly treated with 
lanreotide combination therapy between 2006 and 2011. 108 patients treated at 44 Spanish Endocrinology 
Departments were analyzed separately: 61 patients received lanreotide/cabergoline (cabergoline cohort) and 47 
lanreotide/pegvisomant (pegvisomant cohort). 
Results 
Patient median age was 50.8 years in the cabergoline cohort and 42.7 years in the pegvisomant cohort. Prior medical 
treatments were somatostatin analogue (SSA) monotherapy (40 [66%] patients) or dopamine agonists (7 [11%] 
patients) in the cabergoline cohort and SSA (29 [62%] patients) or pegvisomant monotherapy (16 [34%] patients) in 
the pegvisomant cohort. Across both cohorts 12 patients were previously untreated, and prior therapy was 
unknown/missing in 4 patients. Median duration of combined treatment was 1.6 years (0.1–6) and 2.1 years (0.4–6.3) 
in the cabergoline and pegvisomant cohorts, respectively. At baseline, median insulin growth factor (IGF)-I values 
were 149% upper limit of normal (ULN) (15–505%) in the cabergoline cohort and 156% ULN (15–534%) in the 
pegvisomant cohort, and decreased to 104% ULN (13–557%) p<0.001 and 86% ULN (23–345%) p<0.0001, 
respectively, at end of study (EOS). Normal age-adjusted values of IGF-I were obtained in 48% of 
lanreotide/cabergoline-treated patients and 70% of lanreotide/pegvisomant-treated patients at EOS. There were no 
significant changes in hepatic, cardiac or glycaemic parameters in either cohort. 
Conclusion 
In clinical practice lanreotide treatment combinations are useful options for patients with acromegaly when 
monotherapy is insufficient; particularly, the combination of lanreotide and pegvisomant in patients not controlled 
with either SSA or pegvisomant alone has high efficacy and is well-tolerated. 
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Resumen 
Propósito 
Describir el uso de lanreotida en combinación terapéutica en acromegalia en la práctica clínica. 
Pacientes y métodos 
ACROCOMB es un estudio observacional, retrospectivo, de pacientes con acromegalia activa tratados en centros 
hospitalarios españoles con lanreotida en combinación con cabergolina o pegvisomant entre 2006 y 2011. Se 
revisaron los datos clínicos de 108 pacientes tratados en 44 departamentos de endocrinología: 61 pacientes recibieron 
lanreótido/cabergolina (cohorte cabergolina) y 47 lanreotida/pegvisomant (cohorte pegvisomant). 
Resultados 
La edad mediana de los pacientes fue de 50,8 años en la cohorte de cabergolina y 42,7 años en la de pegvisomant. 
Los tratamientos médicos previos a la combinación con lanreótido fueron análogos de somatostatina (SSA) en 
monoterapia (40 [66%] pacientes) o agonistas de la dopamina (7 [11%] pacientes) en la cohorte de cabergolina y SSA 
(29 [62%] pacientes) y pegvisomant en monoterapia (16 [34%] pacientes) en la de pegvisomant. Doce pacientes no 
habían recibido tratamiento previo y en 4 pacientes se desconocía la terapia previa. La mediana de duración del 
tratamiento fue de 1,6 años (0,1-6) y 2,1 años (rango 0,4 a 6,3) en las cohortes de cabergolina y pegvisomant, 
respectivamente. Al inicio del estudio el valor mediano del factor de crecimiento de insulina-I era 149% el límite 
superior normal (LSN) (15-505%) en la cohorte de cabergolina y 156% LSN (15-534%) en la de pegvisomant. Al 
final del estudio se redujeron a 104% LSN (13-557%) p<0,001 y 86% LSN (23-345%) p<0,0001, respectivamente. 
Al final del estudio, se reportaron valores normales de factor de crecimiento de insulina-I ajustados por edad en el 
48% de los pacientes tratados con lanreotida/cabergolina y 70% de los tratados con lanreotida/pegvisomant. No hubo 
cambios significativos en los parámetros hepáticos, cardíacos o glucémicos. 
Conclusión 
En la práctica clínica las combinaciones con lanreotida son una opción útil en el tratamiento de pacientes con 
acromegalia que no está bien controlada en monoterapia, ya sea con SSA carbegolina o pegvisomant; 
particularmente, la combinación de lanreotida y pegvisomant tiene una alta eficacia y se tolera bien. 
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Introduction 
Acromegaly is a rare chronic disorder characterized by increased growth hormone (GH) secretion and 
elevated insulin-like growth factor-I (IGF-I) levels.
1,2
 In Spain, there is a prevalence of approximately 60 
cases per million, but estimates vary between 15.7 and 75.8 in different regions.
3–5 
 
Three drug classes are available for medical therapy: somatostatin analogues (SSA), dopamine 
agonists, and GH receptor antagonists, namely pegvisomant.
1,2
 SSAs, such as lanreotide or octreotide are 
administered as first-line therapy or as second-line therapy in patients undergoing unsuccessful surgery 
and are currently considered a cornerstone in the treatment of acromegaly.
6 
 
Historically, dopamine agonists have been used in the treatment of acromegaly but their efficacy as 
monotherapy is low.
2,7
 Current guidelines recommend that dopamine agonists be considered particularly 
in patients with mild biochemical activity, such as in the setting of modestly elevated serum IGF-I levels, 
with or without concomitant treatment with SSAs.
1,8
 Efficacy of the addition of dopamine agonist 
cabergoline in patients partially responding to SSA,
9–14
 has been reported to be 52% in terms of 
normalization of IGF-I as noted in the meta-analysis by Sandret et al.
15
 Pegvisomant is often used as a 
long-term medical therapy in patients with inadequate response or complete resistance to SSAs.
1,16–19
 In 
patients with an inadequate response to SSAs, the addition of weekly pegvisomant to full-dose SSA 
therapy may be effective for further lowering of IGF-I levels.
1,20–23
 and offers the benefit of reduced 
pegvisomant injection frequency. In a study of long-term weekly pegvisomant in combination with long-
acting SSAs in 141 patients with acromegaly with persistently elevated IGF-I levels (>1.2× upper limit of 
normal [ULN]) or poor quality of life after 6 months of SSAs monotherapy, 97% of patients derived 
efficacy (defined as the lowest measured IGF-I level during treatment).
24 
 
Evidence from real-life scenarios is a research priority, especially in acromegaly, where multiple large 
clinical trials are not possible. Specifically, it is important to show that evidence from randomized clinical 
trials such as treatment schedules, clinical and economic outcomes, could be translated to real-life setting 
and to show that treatment patterns and clinical outcomes are similar in real-world patients. A systematic 
review of evidence from real-life scenarios on treatment of acromegaly concluded that although 
definitions of disease control varied across studies in different real-world settings, approximately half of 
acromegaly patients have uncontrolled disease.
25
 The aims of this retrospective study were to evaluate the 
real-world efficacy (biochemical control and tumour size) and safety of the SSA lanreotide treatment 
combinations for acromegaly in routine clinical practice. 
Methods 
ACROCOMB, a retrospective observational multicentre study of the Spanish Society of 
Endocrinology and Nutrition (SEEN), evaluated the clinical use of lanreotide combined with cabergoline 
or pegvisomant in patients with active acromegaly. This study included data from the clinical histories of 
108 patients treated between 2006 and 2011 in 44 Spanish centres with lanreotide/cabergoline (N=61, 
cabergoline cohort) or lanreotide/pegvisomant (N=47, pegvisomant cohort). 
 
Criteria for including a patient into the study were: (1) having received medical treatment for 
acromegaly with a single agent without achieving adequate control or (2) having a mixed GH and 
prolactin pituitary adenoma in which combined treatment with lanreotide was indicated as a first 
pharmacologic option. Additionally, patients should have been treated with lanreotide (Somatuline 
Autogel injections, IPSEN) and cabergoline or pegvisomant (Somavert injections, Pfizer) following the 
prescribing information and the specific practices at each centre. Furthermore, patients were required to 
have a reported GH and IGF-I value before initiating combination treatment and at least one value for GH 
and IGF-I during combined treatment. IGF-I and GH were measured locally at each centre following 
local laboratory protocols. The ULN for IGF-I was determined for the immunoassay used at each 
participating centre. Inmulite (Siemens) was used in approximately 70% of the patients, while in the other 
30% the Liason (DiaSorin) and the iSYS assay (IDS) were used. The IGF-I values are reported as %ULN 
and are age-adjusted. Patients with normalized age-adjusted IGF-I values are those with IGF-I values 
≤100% ULN. 
 
Efficacy was assessed by age-adjusted IGF-I levels, age-adjusted prolactin levels, and GH levels at 
baseline, after 6 months of treatment and at the end of the study (EOS). EOS was considered as the last 
registered visit in which a patient was receiving the combined treatment. Information on the radiologic 
evaluations performed at baseline or at EOS was also recorded if available. A clinically significant 
reduction in tumour size was defined as a decrease >2mm in microadenoma or a decrease >20% in 
macroadenoma and an increase was defined as growth of >2mm in microadenoma or growth of >20% in 
macroadenoma. Safety was assessed by the detection of the reported adverse events and their potential 
related causality with lanreotide, cabergoline, or pegvisomant as identified by the treating physician. 
Specific safety assessments focused on hepatic, cardiac and glycaemic adverse events were also collected. 
Hepatic function tests included the measurement of alanine aminotransferase (ALT), aspartate 
aminotransferase (AST), and gamma-glutamyltransferase (GGT) levels at baseline and at EOS. Patients 
in which pegvisomant was incorporated to their treatment regimen with lanreotide had liver test functions 
every 4–6 weeks for the first six months of therapy. Hyperglycaemia was assessed by measuring basal 
glycaemia and Hb1Ac at baseline and at EOS. When indicated, echocardiograms were used to detect 
cardiac abnormalities. 
 
Descriptive summary statistics are presented for all variables. The following variables were evaluated 
in a univariate and multivariate analysis: baseline values of GH, baseline values of IGF-I, radiotherapy, 
age, final lanreotide dose, final cabergoline dose, and duration of combined treatment. An analysis of 
variance (ANOVA) of repeated measures (time factor) was used to study the possible evolution of 
quantitative variables (such as GH). A two-way ANOVA test was used when the effect of another factor 
was being assessed. In the case of categorical variables, a chi-squares test was used. A multivariate 
logistic regression was used to analyze the variables’ dependency on the normalization of final IGF-I 
values (normal up to 100% of ULN). Statistical significance was considered for a p value <0.05. All 
analyses were performed with the statistical software package SPSS (v20.0). 
 
The ACROCOMB study was conducted in accordance with Good Clinical Practice/regulatory 
guidelines and relevant local legislation by the Spanish Agency for Medicines and Health Products 
(AEMPS). The study was authorized by the Ethics Committee of the participating hospitals. The 
ACROCOMB study was sponsored by Spanish Society of Endocrinology and Nutrition (SEEN) and 
funded by Ipsen Pharma, Spain. 
  
Results 
Patient characteristics 
The median patient age was 50.8 years in the cabergoline cohort and 42.7 years in the pegvisomant 
cohort (Table 1). 
Table 1. Baseline characteristics and prior non-pharmacologic treatment. 
   
Cabergoline cohort 
N=61   
Pegvisomant cohort 
N=47    
   
Age (mean±SD)   50.08±14.4 years   45.3±14.5 years   
Sex 
Male   20 (32.8%)   19 (40.4%)   
Female   41 (67.2%)   28 (59.6%)   
BMI (mean±SD)   28.75±5.9   29.8±5.2   
Time since diagnosis (mean±SD)   5.43±6.7 years   7.6±7.7 years   
Maximum diameter at diagnosis (mean±SD)   21.91±11.6mm   25.8±9.8mm   
Comorbidities at baseline 
Hypertension   23 (37.7%)   20 (42.6%)   
Diabetes   15 (24.6%)   16 (34.0%)   
Cardiopathy   7 (11.5%)   4 (8.5%)   
Gallstone   6 (9.8%)   5 (10.6%)   
Cholecystectomy   3 (4.9%)   2 (4.3%)   
High alcohol intake   3 (4.9%)   2 (4.3%)   
Hepatopathy   3 (4.9%)   1 (2.1%)   
Prior treatment 
Surgery   50 (82.0%)   44 (93.6%)   
Number of surgeries (1/2) 
1   50 (82.0%)   40 (85.1%)   
2   11 (18.0%)   7 (14.9%)   
Time since surgery (mean±SD)   5.5±5.3 years   6.1±7.2 years   
Maximum diameter after surgery (mean±SD)   16.86±9.9mm   15.4±10.3mm   
Radiotherapy (RT)   24 (39.3%)   29 (61.7%)   
Fractionated stereotactic radiotherapy (FSRT)   10 (16.3%)   15 (31.9%)   
Time since FSRT (mean±SD)   4.75±6.8 years   2.3±2.7 years   
Conventional RT   7 (11.5%)   7 (14.8%)   
Time since conventional RT (mean±SD)   15.5±13.3 years   12.6±6.6 years   
Radiosurgery   7 (11.5%)   7 (14.8%)   
Time since radiosurgery (mean±SD)   3.4±4.1 years   3.2±2.5 years   
   
 
  
Cabergoline cohort 
The main reason reported for receiving the combination of lanreotide and cabergoline was hormonal 
control in patients partially responsive to SSAs (43 patients, 70.5%). Eleven patients (18.0%) had a mixed 
GH/prolactin tumour diagnosis and had not received prior pharmacologic treatment. Prior therapy was 
unknown/missing in 3 (5%) patients. Prior pharmacologic treatment in the remaining 47 patients was a 
dopamine agonist in 7 patients (11.5%), octreotide in 6 patients (9.8%) and lanreotide monotherapy in 34 
(55.7%) patients. 
Pegvisomant cohort 
Failure of monotherapy with SSAs or pegvisomant was also the main reason for administering 
lanreotide and pegvisomant. Of note, in 4 patients there were 2 medical reasons noted for receiving 
combination therapy and 1 patient had 3 different reasons. Thirty patients (67.5%) were partial SSA 
responders and 10 patients (21.3%) had insufficient response to the pegvisomant dose received (mean 
dose of 20mg/day). Six patients achieved biochemical control with either SSA or pegvisomant 
monotherapy, but received combination therapy for other reasons. Other reasons for receiving lanreotide 
and pegvisomant were tumour growth control in 5 patients, headache control in 4 patients and patient's 
convenience/comfort and economic savings, both in 1 patient each. An “other” reason was listed for 1 
patient with active acromegaly after surgery and radiotherapy. Overall, with the inclusion of this patient, 
there were 41 patients (87.2%) with poor biochemical control. 
 
Medical treatment immediately prior to receiving lanreotide and pegvisomant was long-acting 
lanreotide in 26 patients (55.3%) and pegvisomant in 16 patients (34.0%). Two patients were receiving 
long-acting octreotide and 1 patient was receiving lanreotide and cabergoline before switching to the 
combination of lanreotide and pegvisomant. There was only 1 patient who was not receiving any medical 
treatment and concomitantly initiated both lanreotide and pegvisomant; the reason to initiate treatment 
with both drugs was not specified in this particular case. Furthermore, there was 1 patient for whom there 
were no data on pharmacological treatment immediately prior to initiating the combination. 
Treatment 
The mean (median [range]) duration of treatment with lanreotide and cabergoline was 2.3±1.9 years 
(1.6 years [0.1–6]), and it was 2.5±1.7 years (2.1 years [0.4–6.3]) with lanreotide and pegvisomant. 
Cabergoline cohort 
Throughout the study, the median doses of lanreotide in the cabergoline cohort increased slightly from 
90mg/month at baseline to 120mg/month (60–240) at EOS. The mean dose of lanreotide was 
95.7±25.1mg/month at baseline and 109.2±38.2mg/month at EOS. There were several patients receiving 
an extended lanreotide treatment regimen (every 6 or every 8 weeks) at baseline (7 patients, 11.5%) and 
at EOS (8 patients, 13.1%). Furthermore, 26 patients (42.6%) were receiving <120mg/month lanreotide at 
baseline and 14 patients (23.0%) at EOS. The median weekly dose of cabergoline (1.0mg/week) did not 
change throughout the study, ranging from 0.25–7 at baseline to 0.25–14 at EOS. There was an increase 
in the mean cabergoline dose from 1.2±1.1mg/week at baseline to 1.9±2.3mg/week at EOS. The initial 
and final dosing regimens of lanreotide and cabergoline can be found in Fig. 1. 
  
 
 
 
Figure 1. Doses of lanreotide (a) and cabergoline (b) at baseline and end-of-study (EOS) in the cabergoline cohort and doses of 
lanreotide (c) and pegvisomant (d) at baseline and EOS in the pegvisomant. *Includes 10 patients receiving 60mg/4wk and 6 
patients receiving 120mg/8wk at baseline as well as 6 patients receiving 60mg/4wk and 5 patients receiving 120mg/8wk at EOS. 
†Includes 1 patients receiving 120mg/6wk at baseline and 3 patients receiving 120mg/6wk at EOS. EOS: end of study. *Includes 1 
patient receiving 90mg/8wk at EOS. †Includes 2 patients receiving 60mg/4wk, 3 patients receiving 120mg/8wk at baseline and 2 
patients receiving 90mg/6 week, 4 patients receiving 120mg/8wk at EOS. *Includes 5 patients receiving 120mg/6wk at baseline and 
3 patients receiving 120mg/6 week at EOS. 
Pegvisomant cohort 
The median monthly lanreotide dose did not change in the pegvisomant cohort. It was 120mg/month 
(range 60–240mg/month) at baseline and 120mg/month (range 45–240mg/month) at EOS. The mean dose 
of lanreotide was 107.0±29.2mg/month at baseline and 106.3±30.9mg/month at EOS. An extended 
regimen of lanreotide (every 6 or every 8 weeks instead of monthly) was administered to 8 patients 
(17.0%) at baseline and to 8 patients (17.0%) at EOS. Furthermore, 9 patients (19.1%) were receiving 
<120mg/month lanreotide at baseline and 8 patients (17.0%) at EOS. The median/mean weekly 
pegvisomant doses increased from 70mg (range 10–210mg)/91.7±48.7mg at baseline to 105mg (10–
210)/104.7±50.0mg at EOS. The initial and final dosing regimens of lanreotide and pegvisomant can be 
found in Fig. 1. 
  
Efficacy 
Biochemical control 
IGF1 decreased from baseline to EOS in the majority of patients (Fig. 2). 
 
 
 
Figure 2. Percent change vs baseline value of IGF-I in each individual patient, overall (a) and value-specific (b) in the cabergoline 
cohort and overall (c) and value-specific (d) in the pegvisomant cohort. Patient 2, 39, and 60 had a negligible change from baseline 
to EOS and do not show up as bars in (a). *There was one patient (see number 14 in d) with a baseline value of 15% and increased 
to 94% ULN; therefore there was a 526% change from baseline. This patient is not plotted in c. IGF-I: insulin growth factor; EOS: 
end of study. 
Cabergoline cohort 
The combination of lanreotide and cabergoline treatment led to significant decrease in both the 
median IGF-I and prolactin values (Table 2), and to an increase of the percentage of patients with values 
of GH <2.5ng/ml, with normal age-adjusted values of IGF-I and prolactin, as well as those reaching both 
GH and IGF-I treatment goals (Fig. 3). Few patients reached a level of GH <1.0ng/ml. By the EOS, 29 
patients (48%) had normalized IGF-I values. In 8 patients with normal baseline values of IGF-I, the 
reasons for starting the combination were high prolactin levels and GH values >2.5ng/ml. It is important 
to note that among the 32 patients (52%) that did not have normalized values of IGF-I at EOS, 2 were 
receiving monthly doses of lanreotide <120mg and 18 patients were receiving weekly doses of 
cabergoline <2mg. At EOS both the lanreotide and the cabergoline doses were lower in patients with 
normalized IGF-I (lanreotide, median: 90mg/month [range 60–120mg/month]; mean: 
89.0±24.31mg/month and cabergoline, median: 1.0mg/week [range 0.25–5.0mg/week]; mean: 
1.4±1.2mg/week) than in patients with elevated IGF-I (lanreotide, median: 120mg/month [range 60–
240mg/month]; mean: 127.5±39.6mg/month and cabergoline, median: 1.5mg/week [range 0.25–
14mg/week]; mean:2.4±2.8mg/week). 
Table 2. Biochemical values. 
   
Baseline   6 months   EOS   
 
Cabergoline cohort (N=61) 
GH, median (25th–75th percentile)   4ng/ml (2–8)   3ng/ml (1–7)**   2ng/ml (1–4)*   
IGF-I, median ULN (range)   149% ULN 
(15–505%)   
117% ULN 
(13–557%)   
104% ULN* 
(13–557%)   
Prolactin, median ULN (range)   88% ULN 
(0–4000%)   
7% ULN* 
(0–233%)   
5% ULN* 
(0–807%)   
Pegvisomant cohort (N=47) 
IGF-I, median ULN (range)   165% ULN 
(15–534%)   
85% ULN* 
(11–263%)   
86% ULN* 
(23–345%)   
    
 
EOS: end of study; GH: growth hormone; IGF: insulin growth factor; ULN: upper limit of normal. 
* p<0.001 vs baseline. 
** p<0.022 vs baseline. 
 
 
 
 
Figure 3. Patients with age-adjusted normalized biochemical values. CAB: cabergoline cohort; EOS: end of study GH: growth 
hormone; IGF-I: insulin growth factor; PEG: pegvisomant cohort; PRL: prolactin. 
In a multivariate analysis, a higher probability of normalization of IGF-I levels at EOS was associated 
with higher final dose of lanreotide and longer duration of treatment (Table 3). In the multivariate 
analysis, prior radiotherapy did not affect the biochemical outcome (p=0.072). However, at the EOS 
timepoint, fewer patients without prior radiotherapy had normalized IGF-I values (38% vs 48% in the 
overall cabergoline cohort; Table 4). 
 
  
Table 3. Univariate and multivariate analyses. 
   Cabergoline cohort  Pegvisomant cohort 
Variables   
Univariate 
p value   
Multivariate* 
p value   
OR   95% CI    
Univariate 
p value   
       
Sex   0.586   –   –   –    0.195   
Baseline GH value   0.395   –   –   –    1.0   
Baseline IGF-I value   0.022   0.022   0.041   0.003–0.632    0.653   
Radiotherapy   0.072   –   –   –    0.516   
Age   0.941   –   –   –    0.583   
Dose of lanreotide at EOS   <0.0001   <0.0001   1.071   1.033–1.111    0.322   
Dose of cabergoline at EOS   0.065   –   –   –    0.566   
Duration of treatment   0.012   0.004   0.490   0.301–0.798    0.004   
       
 
CI: confidence interval; GH: growth hormone; IGF: insulin growth factor; EOS: end of study; OR: odds ratio. 
* The model is predictive (AUCROC=0.917, p<0.001) and is correct because the adjustment bond (test of Hosner & Lemeshow) is 
not significant (p=0.513) indicating that there are no differences between the observations and the predictions. 
Table 4. IGF-I values in patients who had not received prior radiotherapy. 
   Baseline   6 months   EOS   
    
Cabergoline cohort (n=37)   n=37   n=37   n=37   
IGF-I values, median ULN (range)   144% ULN 
(15–505%)   
117% ULN 
(13–376%)   
117% ULN 
(13–376%)   
Normalized IGF-I, n (%)   5 (13.5%)   15 (40.5%)   14 (37.8%)   
Pegvisomant cohort (n=18)   n=18   n=18   n=18   
IGF-I values, median ULN (range)   145% ULN 
(85–464%)   
69% ULN 
(41–263%)   
85.5% ULN 
(35–216%)   
Normalized IGF-I, n (%)   1 (5.6%)   14 (77.8%)   14 (77.8%)   
    
 
EOS: end of study; IGF: insulin growth factor; ULN: upper limit of normal. 
Pegvisomant cohort 
Treatment with lanreotide and pegvisomant significantly decreased median IGF-I values after 6 
months of treatment and at EOS (Table 2) and led to an increase of patients with normal age-adjusted 
values of IGF-I, by the EOS, 33 patients (70.2%) had normalized IGF-I values (Fig. 3). 
 
As noted earlier, the combination of lanreotide and pegvisomant was administered mainly due to 
biochemical failure of SSA (n=30) or pegvisomant (n=10) monotherapy. In these 40 patients, median 
IGF-I values were 172% ULN (71–534%) at baseline and significantly decreased to 90% ULN (41–
263%) at 6 months and 86% ULN (33–345%) at EOS. 
  
Of the 14 patients (29.8%) without normalized values of IGF-I at EOS, 4 patients were receiving 
doses of lanreotide <120mg/month and 9 patients were receiving doses of pegvisomant <140mg/week, 
below the theoretical maximal therapeutic dose of 210mg/week. At EOS both the lanreotide and the 
pegvisomant doses were lower in patients with normalized IGF-I (lanreotide, median: 120mg/month 
[range 45–120mg/month]; mean: 102.6±24.1mg/month and pegvisomant, median: 105mg/week [range 
10–210mg/week]; mean: 101.7±46.9mg/week) than in patients with elevated IGF-I (lanreotide, median: 
120mg/month [range 60–240mg/month]; mean: 115.0±42.7mg/month and pegvisomant, median: 
105mg/week [range 15–210mg/week]; mean: 111.9±58.0mg/week). 
 
In a univariate analysis, longer treatment duration was significantly associated with a higher 
normalization of IGF-I levels (p=0.004). The mean treatment duration was 2.9±1.7 years in patients with 
normal age-adjusted IGF-I (≤100%) and in patients with elevated IGF-I (>100%) the mean treatment 
duration was 1.6±1.2 years. The IGF-I levels did not decrease in 7 patients: 2 of these patients had normal 
age-adjusted IGF-I (≤100%), both at baseline and at EOS; 1 of these patients had normal age-adjusted 
IGF-I at baseline that increased slightly to 106% ULN; the IGF-I values in the other 4 patients were 
above 100% ULN at baseline and had increases that ranged from 16% to 71%. The pharmacologic 
treatment that these 7 patients were receiving immediately prior to the lanreotide/pegvisomant 
combination was monotherapy with lanreotide (n=2), octreotide (n=1), and pegvisomant (n=4). At EOS, 
in these 7 patients the mean monthly dose of lanreotide was 124.3±55.9mg and the mean weekly dose of 
pegvisomant was 118.6±74.9mg. Five patients were receiving daily pegvisomant and 2 patients were 
receiving pegvisomant on a weekly basis at EOS. 
Tumour size 
Treatment with the lanreotide combinations led to tumour size decrease or stabilization. 
Cabergoline cohort. At EOS 34 of 41 (82.9%) patients had significant residual tumour by MRI. After 
treatment with lanreotide and cabergoline, 7 of 34 (20.5%) patients had a reduction in tumour size, while 
in 26 of 34 (76.5%) patients the tumour remained stable, and in 1 of 34 (2.9%) patients the tumour size 
increased. 
Pegvisomant cohort. At EOS 29 of 36 (80.6%) patients had residual tumour by MRI. After treatment 
with lanreotide and pegvisomant, 2 of 29 (6.9%) patients had a reduction, 26 of 29 (89.7%) patients had 
stabilization, and 1 of 29 (3.4%) patients had an increase in tumour size. 
  
Safety 
There were no significant changes in hepatic or glycaemic parameters (Table 5). 
Table 5. Specific safety assessments. 
 
Baseline   EOS   p value   
 
Cabergoline cohort (N=61) 
Liver enzymes 
AST (normal/1–2.9 ULN)   n=49 (49/0)   n=54 (54/0)      
ALT (normal/1–2.9 ULN)   n=49 (48/1)   n=54 (52/2)   1   
GGT (normal/1–2.9 ULN)   n=46 (43/3)   n=51 (49/2)   1   
Cardiac assessment with echocardiogram   n=13   n=14      
Abnormal valve   4 (30.8%)   4 (28.6%)      
Ventricular hypertrophy   5 (38.5%)   3 (21.4%)      
Basal glycaemia, median (range)   94mg/dl (68–154)   97mg/dl (48–163)   0.471   
HbA1c, median (range)   6% (5–8)   6% (5–8)   0.248   
Pegvisomant cohort (N=47) 
Liver enzymes 
AST (normal/1–2.9 ULN)   n=39 (39/0)   n=38 (37/1)      
ALT (normal/1–2.9 ULN)   n=40 (39/1)   n=39 (37/2)   1   
GGT (normal/1–2.9 ULN)   n=37 (35/2)   n=37 (35/2)   1   
Cardiac assessment with echocardiogram   n=11   n=5      
Abnormal valve   5 (45.5%)   2 (40.0%)      
Ventricular hypertrophy   4 (36.4%)   1 (20.0%)      
Basal glycaemia, median (range)   103mg/dl (77–202)   99mg/dl (75–213)   0.291   
HbA1c, median (range)   6.5% (5–10)   6% (5–9)   0.593  
    
 
ALT: alanine transaminase; AST: aspartate transaminase; GGT: gamma-glutamyl transferase. 
Cabergoline cohort 
There were 54 adverse events reported in 36 (59.0%) of the patients. The main adverse event during 
treatment was headache, reported 17 times in 9 patients, and apparently unrelated to treatment with 
lanreotide or cabergoline (as determined by the treating physician). Headache was reported as an adverse 
event once in 5 patients, twice in 2 patients, and four times in 2 patients. Further analyses of the patients 
with headache did not reveal a correlation with disease control. Among these 9 patients, normalized IGF-I 
levels were reported in 1 (11%) patient at baseline and in 5 (56%) patients after 6 months of treatment and 
at EOS. Among the 52 patients that did not report headache as an adverse event, there were 7 (14%) 
patients with normalized IGF-I at baseline, 18 (35%) after 6 months, and 24 (46%) at EOS. Other adverse 
events reported included local reactions at the injection site (6 reports, all related to lanreotide), 
abdominal pain (6 reports, all related to lanreotide), biliary sludge (5 reports and related to lanreotide in at 
least 4), diarrhoea (4 reports, all related to lanreotide), nausea (3 reports and related to lanreotide in 2). 
There was 1 report each of hypotension, valvulopathy, and somnolence, all related to cabergoline. 
  
Pegvisomant cohort 
Forty-one adverse events were reported in 22 (46.8%) of the patients. The main adverse event 
reported during the study was local reactions at the injection site, including lipohypertrophy, reported 7 
times; it was deemed twice related to treatment with lanreotide and twice to pegvisomant. Other adverse 
events reported included headache (6 reports, pegvisomant-related in 2), abdominal pain (6 reports, 
lanreotide-related in 2 and pegvisomant-related in 3), nausea (3 reports, unrelated to treatment per clinical 
criteria of the treating physician), biliary sludge (2 reports, unrelated to treatment per clinical criteria of 
the treating physician), biliary calculi (2 reports and related to lanreotide in 1). There was 1 report each of 
tumour growth as an adverse event, diarrhoea, and hepatotoxicity. 
 
The reasons for treatment discontinuation in the cabergoline cohort included lack of efficacy (n=8), 
patient decision (n=2), patient death (n=1) and postradiotherapy improvement (n=1) and in the 
pegvisomant cohort included lack of efficacy (n=2), patient decision (n=2), postradiotherapy 
improvement (n=2) and patient death (n=1). In 2 of the 8 patients that discontinued due to lack of efficacy 
the cabergoline dose was very low (0.5mg/week) at EOS. The status of 3 lanreotide/cabergoline-treated 
patients and 2 lanreotide/pegvisomant-treated patients was unknown due to loss of follow-up. There were 
no discontinuations due to safety reasons in the cabergoline cohort and there was 1 in the pegvisomant 
cohort. Neither the treatment discontinuations nor the patient deaths in either cohort were considered by 
the treating physicians to be related to treatment. 
Discussion 
In this large retrospective series of patients with acromegaly reflecting the use of lanreotide 
combination therapy in routine clinical practice, both the combination with cabergoline and the 
combination with pegvisomant appear to be clinically useful in many patients with active acromegaly not 
fully controlled on monotherapy. Normalization of IGF-I values was reported in approximately half of the 
patients that received lanreotide/cabergoline and in 70% of patients receiving lanreotide/pegvisomant. 
However, even with the best clinical handling with currently available drugs, 50% of patients in the 
cabergoline cohort and 30% in the pegvisomant cohort remained uncontrolled at EOS. Overall, these data 
highlight the heterogeneous nature of the disease, a fact well known by treating clinicians. These 
clinicians must decide on the best treatment for each patient, but are not yet able to rely on biomarkers for 
predicting a positive therapeutic result in the clinical practice. 
 
The result in the cabergoline cohort is similar to what was reported in a meta-analysis of 5 studies of 
cabergoline and SSA treatment in 77 patients, where 52% of patients achieved normal IGF-I levels
15
 and 
to what has been reported in other studies on this combination.
9–14
 In a long-term retrospective study of 66 
acromegalic patients partially responding to octreotide, the addition of cabergoline led to a 73% of the 
patients achieving a GH <2.5ng/mL, 34% of the patients an IGF-1 <1.2× ULN and 30.2% reaching both 
biochemical goals.
26
 The rates of IGF-I normalization in the pegvisomant cohort are lower than those 
reported in controlled clinical studies with this combination therapy, which typically report biochemical 
response in ≥95% of patients,20,21,24,27 but are similar to what has been reported in the study by van der 
Lely et al.,
23
 which specifically selected patients resistant to SSAs, and a recent Italian retrospective study 
of clinical practice,
28
 both of which had a patient population comparable to the ACROCOMB study 
population. 
 
Approximately one third to one half of patients receiving treatment with SSAs have partial but 
insufficient long-term disease control; among these patients, approximately 10-25% can be considered 
highly medically resistant,
6
 meaning a very poor response to maximal doses of SSAs. A challenge as well 
as a clear clinical need in acromegaly is to define biomarkers that could reasonably identify responders 
and non-responders to SSA therapy in order to save time and expenses when treating our patients with 
SSAs, the accepted first option for medical treatment of acromegaly. Moreover, considering that 
acromegaly is usually diagnosed late in the disease evolution, adding delays in controlling GH 
hypersecretion leads to a further comorbility development. While SSAs treatment is the cornerstone of 
acromegaly medical management, it is important to be able to provide effective treatment regimens to 
patients in which hormonal control is not achieved with SSAs monotherapy.
6
 Hormonal control in 
patients partially responding to SSAs was the main reason for receiving combination therapy with an 
additional drug. However, a significant proportion of patients was not receiving the full dose of lanreotide 
or was receiving lanreotide on an extended treatment regimen (>q4w). These situations reflect the reality 
of clinical practice, in which therapeutic agents are administered at lower doses than those theoretically 
possible, potentially due to inadequate dosing by the prescribing physicians, inadequate patient 
compliance, or due to side effects not allowing up titration.
17,18,29,30
 Using lower doses of lanreotide and 
cabergoline/pegvisomant might explain, at least in part, the lack of IGF-I normalization in a subset of 
patients in the ACROCOMB study. Potentially, the use of higher doses of SSAs or increasing the 
administration frequency could help to achieve a higher response to treatment, as reported in the Italian 
randomized controlled study that evaluated the biochemical efficacy of increasing SSAs frequency or 
dose in patients with persistently uncontrolled acromegaly despite conventional titration SSAs therapy.
31 
 
More than half of the patients in the cabergoline cohort that did not achieve IGF-I normalization were 
receiving cabergoline doses below <2mg/week, lower than what has been reported to be effective for 
combination treatment with SSAs. This implies a certain degree of therapeutic inertia in clinical practice 
if we take into account that cabergoline was started after lanreotide in most of the patients. Moreover, one 
third of the patients in the pegvisomant cohort were receiving pegvisomant monotherapy and failed to 
achieve therapeutic goals before the lanreotide combination was started; it is remarkable that so many 
patients were receiving pegvisomant monotherapy, considering that SSA monotherapy is the usual 
recommended first-line treatment. It is notable that many of the patients with poor biochemical control 
had not been titrated to maximal doses of lanreotide or pegvisomant during monotherapy; thus it is 
possible to speculate that higher efficacy might have been attained in the present study if more patients 
would have been titrated to a higher dose. In a survey of European physicians treating patients with 
acromegaly that evaluated their perceived definition of biochemical control and real-world treatment 
decision making, half of the physicians responding considered it acceptable for a patient to have IGF-I 1× 
>ULN, and one fifth considered IGF-I ≥1.5× ULN acceptable.32 This suggests a therapeutic inertia 
situation although the specific reasons why lanreotide or cabergoline/pegvisomant doses were not up 
titrated are not known. 
 
In our study, the combined treatment with lanreotide was well tolerated without significant liver 
enzyme elevations, cardiac abnormalities, or glucose alterations. An increased risk of cardiac valve 
disease has been reported in patients with Parkinson's disease
33
 treated with very high doses of 
cabergoline. However, a study that specifically evaluated the incidence of cardiac abnormalities in a 
series of 42 patients with acromegaly treated with cabergoline did not find a higher incidence of valve 
abnormalities.
34,35
 Moreover, another large cross-sectional study from the UK did not support an 
association between the use of dopamine agonists for the treatment of hyperprolactinemia and cardiac 
valvulopathy.
36
 Hypertransaminasemia is one of the most frequently described adverse events of 
pegvisomant, ranging from 1.2% to 38%, with higher rates of occurrence when patients receive a 
combination with an SSA,
18–21,37
 especially within the first year of combination treatment.
24
 Liver enzyme 
elevations appear to be reversible and normalize either with continued treatment or after discontinuation 
of therapy. It is noteworthy that there were no increases in transaminase levels to more than 3 times the 
ULN in this study and the rates of clinically relevant liver enzyme elevations were lower than in other 
studies with pegvisomant.
21,23,27
 Furthermore, although increases in blood glucose are a known effect of 
SSAs
38,39
 in our study there were no changes in glycaemia and Hb1Ac. 
 
Limitations of our study include its retrospective and observational design. Importantly, data were 
collected retrospectively from several centres using different local laboratories and assays with different 
sensitivities to measure GH and IGF-I and it is widely recognized that there tends to be a lack of 
consistency between results from different labs and assays; however, taken as a whole, results reflect 
what occurs in the clinical practice setting. Moreover, our study has a large number of patients and 
provides a realistic profile of the efficacy and safety of lanreotide combination therapy in clinical practice 
across many Spanish centres. In this sense, the rate of IGF-I normalization is high for clinical series, even 
though in our study neither the patient population nor the treatment provided by the physicians were 
homogeneous, as evidenced by the lower doses of medication received in certain cases. 
 
Overall, our study supports a more relevant role of drug combination in the treatment algorithm of 
acromegaly after insufficient SSA monotherapy response. Future studies involving the definition of 
response biomarkers to specific drugs are required in order to help clinicians in the process of treatment 
decision allowing a quicker normalization of biochemical and hormonal parameters of acromegalic 
patients.
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